In the past week, SPRY stock has gone up by 5.91%, with a monthly decline of -4.98% and a quarterly plunge of -19.67%. The volatility ratio for the week is 8.41%, and the volatility levels for the last 30 days are 7.05% for ARS Pharmaceuticals Inc The simple moving average for the past 20 days is 7.02% for SPRY’s stock, with a 3.61% simple moving average for the past 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
SPRY has 36-month beta value of 0.94. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 51.12M, and currently, short sellers hold a 26.75% ratio of that float. The average trading volume of SPRY on January 16, 2025 was 1.23M shares.
SPRY) stock’s latest price update
The stock of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has increased by 5.72 when compared to last closing price of 11.36.Despite this, the company has seen a gain of 5.91% in its stock price over the last five trading days. investors.com reported 2025-01-13 that Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Analysts’ Opinion of SPRY
Raymond James, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $22, previously predicting the price at $18. The rating they have provided for SPRY stocks is “Strong Buy” according to the report published on August 13th, 2024.
Leerink Partners gave a rating of “Outperform” to SPRY, setting the target price at $20 in the report published on August 12th of the previous year.
SPRY Trading at -8.11% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.12% of loss for the given period.
Volatility was left at 7.05%, however, over the last 30 days, the volatility rate increased by 8.41%, as shares surge +0.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.41% lower at present.
During the last 5 trading sessions, SPRY rose by +5.91%, which changed the moving average for the period of 200-days by +17.51% in comparison to the 20-day moving average, which settled at $11.22. In addition, ARS Pharmaceuticals Inc saw 13.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 50,000 shares at the price of $11.10 back on Jan 06 ’25. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc, valued at $555,065 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, proposed sale 50,000 shares at $11.10 during a trade that took place back on Jan 06 ’25, which means that Shawver Laura is holding shares at $555,065 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -23.84 for the present operating margin
- 0.94 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -19.35. The total capital return value is set at -0.3. Equity return is now at value -22.41, with -21.07 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -449.62. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -16.13.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 444.3. The receivables turnover for the company is 3.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.54.
Conclusion
To put it simply, ARS Pharmaceuticals Inc (SPRY) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
